Nomifensine: effect in Parkinsonian patients not receiving levodopa.
Open Access
- 1 April 1981
- journal article
- research article
- Published by BMJ in Journal of Neurology, Neurosurgery & Psychiatry
- Vol. 44 (4) , 352-354
- https://doi.org/10.1136/jnnp.44.4.352
Abstract
A clinical trial using the anti-depressant nomifensine in Parkinsonism is reported. Eighteen subjects not receiving levodopa participated. The drug had a small, but significant anti-Parkinsonian effect. No troublesome side effects were encountered. In the treatment of Parkinsonism, nomifensine may be considered as an alternative to amantadine or anticholinergics, especially where depression is an added feature.Keywords
This publication has 9 references indexed in Scilit:
- Recent advances in research on Parkinsonism.1978
- Studies on brain metabolism of biogenic amines.British Journal of Clinical Pharmacology, 1977
- SUCCESS AND PROBLEMS OF LONG-TERM LEVODOPA THERAPY IN PARKINSON'S DISEASEThe Lancet, 1977
- Nomifensine in parkinsonism.Journal of Neurology, Neurosurgery & Psychiatry, 1976
- Methlphenidate-like effects of the new antidepressant drug nomifensine (HOE 984)European Journal of Pharmacology, 1976
- Psychiatric symptoms duringL-dopa therapy for Parkinson's disease and their relationship to physical disabilityPsychological Medicine, 1976
- Nomifensine: A potent dopaminergic agonist of antiparkinson potentialPsychopharmacology, 1975
- Effect of nomifensine (Hoe 984), a new antidepressant, on uptake of noradrenaline and serotonin and on release of noradrenaline in rat brain synaptosomesBiochemical Pharmacology, 1974
- Nomifensine: a new potent inhibitor of dopamine uptake into synaptosomes from rat brain corpus striatumJournal of Pharmacy and Pharmacology, 1974